HRMY
Harmony Biosciences Holdings, Inc.
Healthcare · Biotechnology
Deeply Undervalued·Quality 100·RSI 42·DCF +355%·Conviction 85
Investment Thesis — Harmony Biosciences Holdings, Inc.
The market is mispricing Harmony Biosciences as a single-product company with limited growth, reflected in its deeply discounted forward P/E of 7.80 and negative returns. This overlooks the durable revenue stream from Wakix and significant upside potential from its label expansion into new indications like Prader-Willi Syndrome.
Catalysts
- Positive Phase 3 data and subsequent FDA approval for Wakix in Prader-Willi Syndrome.
- Stronger-than-expected sales growth and market share expansion for Wakix in existing narcolepsy and idiopathic hypersomnia indications.
- Advancement of HRMI-002 or other pipeline assets into later-stage clinical trials with promising early data.
Risk Factors
- Clinical trial failure or significant delays for Wakix in Prader-Willi Syndrome.
- Increased competitive pressure from new or existing treatments impacting Wakix's market share and pricing power.
- Unexpected regulatory hurdles or patent challenges to Wakix's exclusivity.
Key Debates
HRMY's 7.85x Fwd P/E will re-rate to 15x by H1 2025
Wakix sustains 17.5% revenue growth into FY25 via new patient starts
Pipeline news will re-rate HRMY's P/E above 10x by Q1 2025